FDA grants EUA to anti-COVID-19 drug molnupiravir

The Food and Drug Administration (FDA) on Thursday granted emergency use authorization (EUA) to anti-COVID-19 drug molnupiravir under brand name Molnarz.

FDA Director General Eric Domingo said this drug will be used on patients with mild to moderate COVID-19.

"This can only be given to adults aged 18 and above, who tested positive for COVID-19 and are at risk of developing severe illness," Domingo said during the Laging Handa briefing.

"Molnupiravir is given twice a day for five days, but should be given as soon as possible after diagnosis. And it should be given within the first five days after the onset of symptoms," he added.

An EUA allows legal administration of the drug in the country but does not allow for commercial selling. 

"[The] Molnarz [brand of molnupiravir] was the first one to apply for an EUA and it was able to comply with our required safety, efficacy and quality. With the EUA on molnupirvair, we will not be issuing Compassionate Special Permit anymore," Domingo pointed out.

"Molnupiravir comes in 200 milligram capsules and should be given during the first five days of COVID-19 symptoms otherwise it will not be useful," he added.

In addition, Domingo said molnupiravir cannot be given to those who are pregnant, those who are using contraceptives and lactating women because of lack of enough data showing that the drug is safe for those belonging to these sectors. — RSJ, GMA News